HOXA9 and acute myeloid leukemia: Similarly, HOXBLINC KD in patient 1292 AML cells also significantly prolonged the survival of the transplanted mice (Supplemental Figure 8C), indicating that loss of HOXBLINC inhibited the leukemogenic potential of NUP98-HOXA9 leukemic cells.